Tags |
|
|
Links |
|
|
Advice You - Medical Billing - GX0 Record Fields 20 Through 23
If you've been following our medical billing series on oxygen billing and the electronic transmission of claims using NSF 3.01 specifications,
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
you probably have been thinking, at least to this point, that this GX0 record isn't too bad. Well, that's all about to change as we start gett
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
ng into the more complex fields of this record with this installment. We pick up our review of the GX0 record with field number 20, which is g
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
ing to take a little bit of explaining in order to make it perfectly clear.
GX0 field 20, position 146, is the inpatient/outpatient indicator.
GX0 field 20, position 146, is the inpatient/outpatient indicator.
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
You have to wonder how the carriers come up with these descriptions because this one does absolutely nothing to clarify exactly what this fiel
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
is for. This indicator is a simple Y or N answer, for yes or no. But it's not to tell the carrier if the patient was an inpatient or an outp
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
tient at the facility. This indicator is used to tell the carrier if the tests reported in fields 22 or 23 were performed exactly within one d
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
y of discharge from the inpatient facility or if the tests were performed while the patient was at home while in a chronic stable state. If yo
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
don't understand what that means, that's okay. You are not alone. For clarification of the second part of this explanation, consult with you
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
carrier. If you can answer yes to either of those conditions, then a Y is transmitted to the carrier. If you can't answer yes to either of t
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
ose conditions then an N is transmitted to the carrier.
GX0 field 21, positions 147 - 211, is filler. Usually, filler is thrown it at the end
GX0 field 21, positions 147 - 211, is filler. Usually, filler is thrown it at the end
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
of a record when there is no more data to report. So why put filler in the middle of a record when there is more data to submit? For those o
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
you who have been scratching your head wondering they why of this, the answer is finally here. The reason is because the data that follows wa
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
intended to be mapped to coincide with other related fields from other CMNs. As it turned out with NSF 3.01 specifications, this never happen
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
d. So the result is that we have a lot of wasted space in the middle of a record that has everybody, billers especially, totally confused. Le
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
's hear it for NSF regulations.
GX0 field 22, positions 212 - 214, is the arterial blood gas. This is a three digit field with an implied dec
GX0 field 22, positions 212 - 214, is the arterial blood gas. This is a three digit field with an implied dec
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
mal. Valid values are from 00.0 to 99.9. This field tells the carrier what the arterial blood gas results were that were taken on or before t
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
e date of this certification.
GX0 field 23, positions 215 - 217, is the oxygen saturation. This field is similar to the one above as it is al
GX0 field 23, positions 215 - 217, is the oxygen saturation. This field is similar to the one above as it is al
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
o a three digit field with an implied decimal. However, this field tells the carrier what the oxygen saturation tests results were on or befor
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
the date of this certification.
In our next installment on medical billing, we'll be covering the GX0 record, picking up with field number 24
In our next installment on medical billing, we'll be covering the GX0 record, picking up with field number 24
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/2045/adviceyou-Medical-Billing--GX0-Record-Fields-20-Through-23.html">Medical Billing - GX0 Record Fields 20 Through 23</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/2045/adviceyou-Medical-Billing--GX0-Record-Fields-20-Through-23.html]Medical Billing - GX0 Record Fields 20 Through 23[/url]
Related Articles:
How To Write A Headline That Converts More Visitors Into Customers
A Simple Trick That Increases Attendance By 30%
Bookmark it:
|